Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study is to evaluate the safety of SU011248 (Sunitinib/Sutent) in combination with docetaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Docetaxel; Sunitinib

Criteria

Inclusion Criteria:

• Breast cancer with evidence of unresectable, locally recurrent or metastatic disease

• Candidate for treatment with docetaxel

Exclusion Criteria:

• Prior chemotherapy in the advanced disease setting

• Inflammatory breast cancer

• HER2 positive disease